Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Inclusion Criteria: * Diagnosis of metastatic or unresectable advanced solid tumors (solid tumors must be measurable) or relapsed/refractory multiple myeloma for which the disease has progressed despite available standard therapies or for which no standard therapy exists. * Life expectancy of at least 12 weeks. * Eastern Cooperative Oncology Group (ECOG) Performance status of 0, 1, or 2 (not declining within 2 weeks prior to study day 1). Exclusion Criteria: * Central nervous system (CNS) metastases. * Chemotherapy or other anti-cancer therapy within 4 weeks prior to study day 1, and/or nitrosoureas within the 6 weeks prior to study day 1. * Lack of recovery from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy with the exception of alopecia. * Radiation therapy within 4 weeks prior to study day 1. * Clinically significant pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal or genitourinary disease unrelated to underlying solid tumor or multiple myeloma * Significant cardiac risk (e.g. history of myocardial infarction, unstable angina, pulmonary hypertension, clinically significant arrhythmia, congestive heart failure within 1 year prior to study day 1). * Diagnosis or family history of hereditary hemorrhagic telangiectasia. * Major surgery within 6 weeks prior to study day 1. * Parenteral antibiotics, or any life-threatening or active infection requiring parenteral antibiotic therapy within 1 month prior to study day 1. * Therapeutic anti-coagulation. * Uncontrolled hypertension. * Autoimmune or hereditary hemolysis. * Clinically significant gastrointestinal bleeding or any other clinically significant active bleeding within 3 months prior to study day 1. * Treatment with another investigational drug or device, or approved therapy for investigational use within 28 days prior to study day 1. * Pregnancy or lactation for female patients.